Browse ABCC3

Summary
SymbolABCC3
NameATP-binding cassette, sub-family C (CFTR/MRP), member 3
Aliases MRP3; cMOAT2; EST90757; MLP2; MOAT-D; canalicular multispecific organic anion transporter 2; ABC31; ATP-bind ......
Chromosomal Location17q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Membrane; Multi-pass membrane protein.
Domain PF00664 ABC transporter transmembrane region
PF00005 ABC transporter
Function

May act as an inducible transporter in the biliary and intestinal excretion of organic anions. Acts as an alternative route for the export of bile acids and glucuronides from cholestatic hepatocytes (By similarity).

> Gene Ontology
 
Biological Process GO:0006820 anion transport
GO:0006869 lipid transport
GO:0010876 lipid localization
GO:0015711 organic anion transport
GO:0015718 monocarboxylic acid transport
GO:0015721 bile acid and bile salt transport
GO:0015849 organic acid transport
GO:0015850 organic hydroxy compound transport
GO:0046942 carboxylic acid transport
GO:0098656 anion transmembrane transport
Molecular Function GO:0005319 lipid transporter activity
GO:0005342 organic acid transmembrane transporter activity
GO:0008028 monocarboxylic acid transmembrane transporter activity
GO:0008509 anion transmembrane transporter activity
GO:0008514 organic anion transmembrane transporter activity
GO:0015125 bile acid transmembrane transporter activity
GO:0015399 primary active transmembrane transporter activity
GO:0015405 P-P-bond-hydrolysis-driven transmembrane transporter activity
GO:0015432 bile acid-exporting ATPase activity
GO:0016820 hydrolase activity, acting on acid anhydrides, catalyzing transmembrane movement of substances
GO:0016887 ATPase activity
GO:0022804 active transmembrane transporter activity
GO:0022853 active ion transmembrane transporter activity
GO:0042623 ATPase activity, coupled
GO:0042625 ATPase coupled ion transmembrane transporter activity
GO:0042626 ATPase activity, coupled to transmembrane movement of substances
GO:0043225 ATPase-coupled anion transmembrane transporter activity
GO:0043492 ATPase activity, coupled to movement of substances
GO:0046943 carboxylic acid transmembrane transporter activity
GO:1901618 organic hydroxy compound transmembrane transporter activity
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG hsa02010 ABC transporters
hsa04976 Bile secretion
Reactome R-HSA-382556: ABC-family proteins mediated transport
R-HSA-194068: Bile acid and bile salt metabolism
R-HSA-1430728: Metabolism
R-HSA-556833: Metabolism of lipids and lipoproteins
R-HSA-159418: Recycling of bile acids and salts
R-HSA-382551: Transmembrane transport of small molecules
Summary
SymbolABCC3
NameATP-binding cassette, sub-family C (CFTR/MRP), member 3
Aliases MRP3; cMOAT2; EST90757; MLP2; MOAT-D; canalicular multispecific organic anion transporter 2; ABC31; ATP-bind ......
Chromosomal Location17q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between ABCC3 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between ABCC3 and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
18619700Hepatocellular CarcinomaPromote immunityOur study demonstrates that MRP3 is a potential candidate for tumor antigen with strong immunogenicity in HCC immunotherapy.
Summary
SymbolABCC3
NameATP-binding cassette, sub-family C (CFTR/MRP), member 3
Aliases MRP3; cMOAT2; EST90757; MLP2; MOAT-D; canalicular multispecific organic anion transporter 2; ABC31; ATP-bind ......
Chromosomal Location17q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of ABCC3 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolABCC3
NameATP-binding cassette, sub-family C (CFTR/MRP), member 3
Aliases MRP3; cMOAT2; EST90757; MLP2; MOAT-D; canalicular multispecific organic anion transporter 2; ABC31; ATP-bind ......
Chromosomal Location17q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of ABCC3 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.050.905
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.5560.503
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.3270.602
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.5890.366
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.8810.717
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.2220.942
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.460.425
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.8010.441
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.0450.971
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.4220.822
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 281.1750.66
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.4580.0244
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of ABCC3 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 141705.9-5.91
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 41407.1-7.11
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277314.82.712.10.0439
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275914.83.411.40.0746
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21179.511.8-2.31
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)131115.418.2-2.81
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38277.93.74.20.636
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 221313.67.75.91
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolABCC3
NameATP-binding cassette, sub-family C (CFTR/MRP), member 3
Aliases MRP3; cMOAT2; EST90757; MLP2; MOAT-D; canalicular multispecific organic anion transporter 2; ABC31; ATP-bind ......
Chromosomal Location17q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of ABCC3. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolABCC3
NameATP-binding cassette, sub-family C (CFTR/MRP), member 3
Aliases MRP3; cMOAT2; EST90757; MLP2; MOAT-D; canalicular multispecific organic anion transporter 2; ABC31; ATP-bind ......
Chromosomal Location17q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of ABCC3. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by ABCC3.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolABCC3
NameATP-binding cassette, sub-family C (CFTR/MRP), member 3
Aliases MRP3; cMOAT2; EST90757; MLP2; MOAT-D; canalicular multispecific organic anion transporter 2; ABC31; ATP-bind ......
Chromosomal Location17q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of ABCC3. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolABCC3
NameATP-binding cassette, sub-family C (CFTR/MRP), member 3
Aliases MRP3; cMOAT2; EST90757; MLP2; MOAT-D; canalicular multispecific organic anion transporter 2; ABC31; ATP-bind ......
Chromosomal Location17q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of ABCC3 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolABCC3
NameATP-binding cassette, sub-family C (CFTR/MRP), member 3
Aliases MRP3; cMOAT2; EST90757; MLP2; MOAT-D; canalicular multispecific organic anion transporter 2; ABC31; ATP-bind ......
Chromosomal Location17q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between ABCC3 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolABCC3
NameATP-binding cassette, sub-family C (CFTR/MRP), member 3
Aliases MRP3; cMOAT2; EST90757; MLP2; MOAT-D; canalicular multispecific organic anion transporter 2; ABC31; ATP-bind ......
Chromosomal Location17q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting ABCC3 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.